BioArctic has announced that the US Patent and Trademark Office (USPTO) has granted a new drug substance patent for the antibody ABBV-0805, invented by BioArctic as a potential treatment of Parkinson's disease.
The patent will take effect on May 24, 2022, and expire in 2041, with the possibility